TimesSquare Capital Management LLC Purchases Shares of 451,593 Xenon Pharmaceuticals Inc. $XENE

TimesSquare Capital Management LLC purchased a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 451,593 shares of the biopharmaceutical company’s stock, valued at approximately $27,258,000. TimesSquare Capital Management LLC owned 0.47% of Xenon Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of XENE. Kestra Advisory Services LLC bought a new stake in shares of Xenon Pharmaceuticals during the 4th quarter valued at $33,000. Danske Bank A S bought a new position in Xenon Pharmaceuticals in the 3rd quarter worth $32,000. Global Retirement Partners LLC bought a new position in Xenon Pharmaceuticals in the 2nd quarter worth $53,000. Caitong International Asset Management Co. Ltd purchased a new stake in Xenon Pharmaceuticals in the 4th quarter worth $43,000. Finally, Axiom Investment Management LLC purchased a new stake in Xenon Pharmaceuticals in the 1st quarter worth $58,000. 95.45% of the stock is owned by hedge funds and other institutional investors.

Xenon Pharmaceuticals Stock Performance

Shares of NASDAQ XENE opened at $62.36 on Tuesday. The company has a market cap of $6.03 billion, a P/E ratio of -13.16 and a beta of 0.62. The firm’s fifty day moving average is $61.57 and its two-hundred day moving average is $55.22. Xenon Pharmaceuticals Inc. has a 52-week low of $35.60 and a 52-week high of $72.66.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.05. During the same quarter in the previous year, the firm posted ($1.07) earnings per share. As a group, analysts forecast that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on XENE. Royal Bank Of Canada decreased their price target on Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating on the stock in a report on Friday, August 7th. Wells Fargo & Company reiterated an “overweight” rating and set a $69.00 target price on shares of Xenon Pharmaceuticals in a research report on Sunday, May 10th. Wall Street Zen raised Xenon Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Monday, July 6th. Finally, HC Wainwright restated a “buy” rating and issued a $74.00 price target on shares of Xenon Pharmaceuticals in a research note on Monday, August 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Xenon Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $77.13.

Insider Buying and Selling

In other Xenon Pharmaceuticals news, Director Steven Gannon sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $64.06, for a total transaction of $640,600.00. Following the completion of the transaction, the director owned 1,870 shares in the company, valued at $119,792.20. This trade represents a 84.25% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Gillian Cannon sold 1,190 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the completion of the sale, the director directly owned 1,455 shares in the company, valued at approximately $77,318.70. The trade was a 44.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 12,512 shares of company stock worth $774,088. Corporate insiders own 2.91% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.